预处理化疗对大B细胞淋巴瘤CAR-T治疗患者淋巴细胞动力学及结局的影响
本研究纳入171例大B细胞淋巴瘤患者,探讨预处理化疗后淋巴细胞计数变化(DLIx)是否可作为药效标志物及其与胚系基因变异的关系。中位DLIx为0.5×10^9/L,完全缓解者DLIx显著更高(p=0.04);低DLIx仅与桥接治疗使用相关(OR 0.4,95%CI 0.2-0.8,p=0.007),并独立关联更短的无进展生存(p=0.02)和总生存(p=0.02)。DLIx与ABCB1、MISP和CPVL等药物代谢及巨噬细胞生物学相关基因变异有关。
要点
- 中位DLIx为0.5×10^9/L(范围0.01-2.75×10^9/L),完全缓解者显著更高(p=0.04)。
- 低DLIx仅与桥接治疗使用相关(OR 0.4,95%CI 0.2-0.8,p=0.007)。
- 低DLIx独立关联更短无进展生存(p=0.02)和总生存(p=0.02)。
核心结论
- 预处理化疗对淋巴细胞计数的影响受桥接治疗使用影响,但淋巴细胞计数变化独立关联疗效。
研究设计与样本
- 研究纳入171例接受CAR-T治疗的大B细胞淋巴瘤患者,其中86例(50%)在白细胞分离后接受桥接治疗。
主要发现
- 中位DLIx为0.5×10^9/L(范围0.01-2.75×10^9/L),完全缓解者DLIx显著更高(p=0.04)。
- 多因素分析显示低DLIx仅与桥接治疗使用相关(OR 0.4,95%CI 0.2-0.8,p=0.007)。
- 低DLIx独立关联更短的无进展生存(p=0.02)和总生存(p=0.02)。
- DLIx与ABCB1、MISP和CPVL等药物代谢及巨噬细胞生物学相关基因变异有关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Conditioning chemotherapy (CCT) has been shown to be essential for optimal efficacy of chimeric antigen receptor (CAR) T-cell therapy. Here, we determined whether the change in absolute lymphocyte count, referred to as delta lymphocyte index (DLIx), may serve as a surrogate marker for pharmacodynamic effects of CCT and whether it associated with germline genetic variants in patients with large B-cell lymphoma (LBCL). One-hundred and seventy-one patients were included, of which 86 (50%) received bridging therapy post-leukapheresis. Median DLIx was 0.5 × 109/L (range, 0.01-2.75 × 109/L) and was significantly higher in patients who achieved complete response (p = 0.04). On multivariate analysis, low DLIx was associated only with use of bridging therapy (odds ratio 0.4, 95% CI 0.2-0.8, p = 0.007). Low DLIx was independently associated with shorter progression-free (p = 0.02) and overall survival (p = 0.02). DLIx was associated with genetic variations related to drug metabolism and macrophage biology such as ABCB1, MISP and CPVL. The impact of CCT on lymphocyte count is affected by use of bridging therapy but change in lymphocyte count is independently associated with efficacy. Studies aimed at investigating macrophage biology in this setting may suggest strategies to increase the efficacy of CCT and improve outcomes.
引用
- Strati P, Jallouk AP, Sun R, et al. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia. 2022. PMID: 36127509. doi:10.1038/s41375-022-01704-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。